ASP 6981

Drug Profile

ASP 6981

Alternative Names: ASP6981

Latest Information Update: 13 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Class Antipsychotics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Schizophrenia

Most Recent Events

  • 16 Jan 2018 Phase-I clinical trials in Schizophrenia (Treatment-experienced) in USA (PO) (NCT03356639)
  • 29 Nov 2017 Astellas Pharma plans a phase I trial for Schizophrenia (Treatment-experienced) in December 2017 (NCT03356639)
  • 31 Jul 2017 Phase-I clinical trials in Schizophrenia in Japan (PO) (Astellas pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top